Australia’s TGA To Stamp Out Clinical Evidence Mistakes By Industry
Executive Summary
The Australian Therapeutic Goods Administration is attempting to clarify its expectations on clinical evidence requirements for medical devices to stop the many errors companies are making in their submissions for market authorization.
You may also be interested in...
Australia’s 'Unrealistic' Randomized Controlled Trial Proposal Comes Under Fire
Industry is not entirely happy with the Therapeutic Goods Administration’s proposed guidelines on clinical evidence requirements.
EMA Probe Finds No Link Between GLP-1s And Suicidal Thoughts & Actions
After reviewing the evidence from non-clinical studies, clinical trials, post-marketing surveillance data and other studies, the European Medicines Agency said there was no need to update the product information for 11 diabetes and weight management drugs.
English Funding For Aquipta Targets AbbVie’s Migraine Drug To 170,000 People
Aquipta is the first oral treatment that NICE has recommended for preventing chronic migraines in the fourth-line setting, and the second oral treatment for episodic migraines in the same setting. The drug has already secured reimbursement in Scotland, Sweden and Israel.